{"id":"https://openalex.org/W4361946576","doi":"https://doi.org/10.1158/1078-0432.c.6527502","title":"Data from A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer","display_name":"Data from A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361946576","doi":"https://doi.org/10.1158/1078-0432.c.6527502"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.c.6527502","doi":"https://doi.org/10.1158/1078-0432.c.6527502","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.c.6527502","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://dx.doi.org/10.1158/1078-0432.c.6527502","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5028472820","display_name":"Johanna C. Bendell","orcid":"https://orcid.org/0000-0001-9426-5891","observed_orcids":["https://orcid.org/0000-0001-9426-5891"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Johanna C. Bendell","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027467209","display_name":"Anna M. Varghese","orcid":"https://orcid.org/0000-0001-5426-0885","observed_orcids":["https://orcid.org/0000-0001-5426-0885"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anna M. Varghese","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068193017","display_name":"David Michael Hyman","orcid":"https://orcid.org/0000-0001-8150-9762","observed_orcids":["https://orcid.org/0000-0001-8150-9762"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David M. Hyman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037195922","display_name":"Todd Michael Bauer","orcid":"https://orcid.org/0000-0002-3078-5043","observed_orcids":["https://orcid.org/0000-0002-3078-5043"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Todd M. Bauer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084349853","display_name":"Shubham Pant","orcid":"https://orcid.org/0000-0001-9281-480X","observed_orcids":["https://orcid.org/0000-0001-9281-480X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shubham Pant","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051346978","display_name":"Sophie Callies","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sophie Callies","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053450523","display_name":"Ji Lin","orcid":"https://orcid.org/0000-0001-7206-6111","observed_orcids":["https://orcid.org/0000-0001-7206-6111"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ji Lin","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-7206-6111","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103649612","display_name":"Ricardo Mart\u00ednez","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ricardo Martinez","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035801178","display_name":"Enaksha R. Wickremsinhe","orcid":"https://orcid.org/0009-0003-0609-823X","observed_orcids":["https://orcid.org/0009-0003-0609-823X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Enaksha Wickremsinhe","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Aaron Fink","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Aaron Fink","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009244604","display_name":"Volker Wacheck","orcid":"https://orcid.org/0000-0003-3962-5932","observed_orcids":["https://orcid.org/0000-0003-3962-5932"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Volker Wacheck","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5069337573","display_name":"Kathleen N. Moore","orcid":"https://orcid.org/0000-0002-5803-0718","observed_orcids":["https://orcid.org/0000-0002-5803-0718"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kathleen N. Moore","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dual-pi3k-mtor-inhibitor","display_name":"PI3K/mTOR dual inhibitor","score":0.9399999976158142},{"id":"https://openalex.org/keywords/mtor-inhibition","display_name":"mTOR inhibition","score":0.9610000252723694},{"id":"https://openalex.org/keywords/dna-pk-inhibition","display_name":"DNA-PK inhibition","score":0.9409999847412109},{"id":"https://openalex.org/keywords/advanced-cancer","display_name":"advanced cancer","score":0.7400000095367432},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.8289999961853027},{"id":"https://openalex.org/keywords/recommended-phase-ii-dose","display_name":"recommended phase 2 dose","score":0.9290000200271606},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.902999997138977},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9079999923706055},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.9020000100135803},{"id":"https://openalex.org/keywords/thrombocytopenia","display_name":"thrombocytopenia","score":0.8330000042915344},{"id":"https://openalex.org/keywords/endometrial-cancer","display_name":"endometrial cancer","score":0.7670000195503235}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7444157600402832},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.6671199202537537},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6477842926979065},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.6336841583251953},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.5972940921783447},{"id":"https://openalex.org/C2778496288","wikidata":"https://www.wikidata.org/wiki/Q6931269","display_name":"Mucositis","level":3,"score":0.5767167806625366},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.49117299914360046},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.48080626130104065},{"id":"https://openalex.org/C2780852908","wikidata":"https://www.wikidata.org/wiki/Q127076","display_name":"Vomiting","level":2,"score":0.4482807517051697},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.43829113245010376},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3426783084869385},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.21719461679458618}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1078-0432.c.6527502","doi":"https://doi.org/10.1158/1078-0432.c.6527502","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.c.6527502","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.c.6527502","doi":"https://doi.org/10.1158/1078-0432.c.6527502","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.c.6527502","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2802449276","https://openalex.org/W2598882746","https://openalex.org/W3036375657","https://openalex.org/W4392698818","https://openalex.org/W2497200850","https://openalex.org/W2104243174","https://openalex.org/W2802053092","https://openalex.org/W2126390772","https://openalex.org/W2771798167","https://openalex.org/W4361950726"],"abstract_inverted_index":{"Abstract":[0],"Purpose:":[1],"The":[2,67,234],"PI3K/mTOR":[3],"pathway":[4],"is":[5,11,239],"frequently":[6],"aberrated":[7],"in":[8,115,126,132,164,191,211,229],"cancer.":[9],"LY3023414":[10,54,94,159,178,220,237],"a":[12,181,192,209,222],"potent":[13],"and":[14,24,41,49,84,131,150,153,199,203,226,248],"selective":[15],"ATP-competitive":[16],"inhibitor":[17,183],"of":[18,32,38,53,117,128,134,184,236],"class":[19],"I":[20,36],"PI3K":[21],"isoforms,":[22],"mTOR,":[23],"DNA-PK.":[25],"Here":[26],"we":[27],"report":[28],"the":[29,33,73],"dose-escalation":[30],"results":[31],"first-in-human":[34],"phase":[35,75],"study":[37],"LY3023414.":[39],"Patients":[40],"Methods:":[42],"A":[43],"3+3":[44],"dose":[45,77],"escalation":[46],"for":[47,61],"once-daily":[48,96,111],"twice-daily":[50,100,121,140],"oral":[51],"dosing":[52,101,122],"was":[55,70,189],"followed":[56],"by":[57,215],"an":[58],"expansion":[59],"cohort":[60],"CYP3A4":[62],"drug\u2013drug":[63],"interaction":[64],"(DDI)":[65],"assessment.":[66],"primary":[68],"objective":[69],"to":[71,179,217],"determine":[72],"recommended":[74],"2":[76],"(RP2D).":[78],"Additional":[79],"objectives":[80],"included":[81,145],"safety,":[82,246],"pharmacokinetics/pharmacodynamics,":[83],"antitumor":[85],"activity.":[86],"Results:":[87],"Forty-seven":[88],"patients":[89,136,206,230],"with":[90,166,194,231],"solid":[91],"tumors":[92],"received":[93],"at":[95,108,137,171],"(20\u2013450":[97],"mg)":[98],"or":[99,157],"(150\u2013250":[102],"mg).":[103],"Dose-limiting":[104],"toxicities":[105],"were":[106,154],"observed":[107,190],"450":[109],"mg":[110,139,241],"(thrombocytopenia,":[112],"hypotension,":[113],"hyperkalemia)":[114],"three":[116,118,127],"patients,":[119,130],"250-mg":[120],"(hypophosphatemia,":[123],"fatigue,":[124],"mucositis)":[125],"four":[129],"one":[133],"15":[135],"200":[138,240],"(nausea).":[141],"Common":[142],"related":[143],"AEs":[144],"nausea":[146],"(38%),":[147],"fatigue":[148],"(34%),":[149],"vomiting":[151],"(32%)":[152],"mostly":[155],"mild":[156],"moderate.":[158],"pharmacokinetics":[160],"demonstrated":[161,177],"dose-dependent":[162],"increase":[163],"exposure":[165],"\u2265":[167],"90%":[168],"target":[169,213],"inhibition":[170],"doses":[172],"\u2265150":[173],"mg.":[174],"DDI":[175],"analysis":[176],"be":[180],"weak":[182],"CYP3A4.":[185],"Durable":[186],"partial":[187],"response":[188],"patient":[193],"endometrial":[195],"cancer":[196],"harboring":[197],"PIK3R1":[198],"PTEN":[200],"truncating":[201],"mutations,":[202],"13":[204],"additional":[205],"(28%)":[207],"had":[208],"decrease":[210],"their":[212],"lesions":[214],"up":[216],"30%.":[218],"Conclusions:":[219],"has":[221],"tolerable":[223],"safety":[224],"profile":[225],"single-agent":[227],"activity":[228],"advanced":[232],"cancers.":[233],"RP2D":[235],"monotherapy":[238],"twice":[242],"daily":[243],"based":[244],"on":[245],"tolerability,":[247],"pharmacokinetic/pharmacodynamic":[249],"data.":[250],"Clin":[251],"Cancer":[252],"Res;":[253],"24(14);":[254],"3253\u201362.":[255],"\u00a92018":[256],"AACR.":[257]},"counts_by_year":[],"updated_date":"2026-10-02T10:15:12.560889","created_date":"2023-04-05T00:00:00"}